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A b s t r a c t
Background: Transcatheter aortic valve implantation (TAVI) is a new method for the treatment of aortic stenosis (AS).
Aim: To evaluate early results of TAVI using transfemoral/transsubclavian approach (TFA/TSA) or transapical approach (TAA)
in patients with severe AS and high risk for surgical aortic valve replacement.
Methods: Between January 2009 and May 2010, 30 high-risk patients underwent TAVI. The primary treatment option was
TFA, and TAA was used if contraindications to TFA were present; one patient underwent the procedure using TSA. Reasons
for selecting TAA were as follows: small diameter (< 7 mm) and/or severe calcification of the iliofemoral arteries, peripheral
atherosclerosis, “porcelain” aorta and a horizontal course of the ascending aorta. Edwards-Sapien or CoreValve devices were
used in all cases, and procedures were performed without the use of cardiopulmonary bypass in a cardiac catheterisation
laboratory.
Results: Mean patient age was 82.46 ± 5.79 years, mean NYHA class was 3.23 ± 0.41, and predicted mean surgical
mortality using logistic Euroscore was 29.18 ± 16.9% (22.72 ± 12.07% in the TFA/TSA group vs 34.6 ± 15.4% in the TAA
group; p = 0.031). Eleven patients were treated using TAA. The valve was implanted successfully in 96% of patients. In-
hospital mortality was 3.3%. Mean 30-day mortality was 6.6% in the entire cohort, 0% in the TFA/TSA group and 18% in the
TAA group. There were no cases of periprocedural myocardial infarction (MI), cardiogenic shock, stroke/transient ischaemic
attack, or need for cardiopulmonary resuscitation. One patient died suddenly three weeks after the procedure; except for
this case, there were no major adverse cardiovascular events (MACCE: MI, cerebrovascular accident, re-do procedure) at 30-
-day follow-up. The TAVI was associated with a significant reduction in the mean maximal aortic gradient in both groups
(from 99.6 ± 22.07 mm Hg to 21.83 ± 9.38 mm Hg post-procedure and to 23.25 ± 9.22 mm Hg at 30-day follow up), with no
cases of severe aortic valve regurgitation. The NYHA class at 30 days improved from 3.23 ± 0.41 to 1.72 ± 0.52 (p = 0.03).
Conclusions: Our results demonstrate lower 30-day complication rate and mortality in the TFA/TSA group. The availability
of several techniques of valve implantation in the group of non-surgical patients with severe AS potentially broadens the
patient population with indications for this treatment.
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INTRODUCTION
Acquired aortic stenosis (AS) is the most prevalent valvular
heart disease that becomes one of the major challenges in
modern cardiology practice due to aging of the population
[1–4]. The AS affects about 5% of patients above 75 years of
age. Medical treatment does not improve prognosis in pa-
tients with severe AS, and the treatment of choice is surgical
aortic valve replacement (AVR) using a mechanical or biolo-
gical valve prosthesis [3, 5]. However, data from the Euro Heart
Survey suggest that significant perioperative mortality in ol-
der patients with comorbidities results in nearly one third of
patients (approximately 3000 patients in Poland) being not
referred for surgery [4, 5].
In recent years, with introduction of a new treatment
modality, transcatheter aortic valve implantation (TAVI),
treatment options in patients with AS requiring invasive
treatment have expanded significantly [4, 6–12]. The gro-
up that might benefit most from the introduction of TAVI
are older patients with multiple comorbidities and a high
risk of major complications, including death, during car-
diac surgery that requires sternotomy and the use of car-
diopulmonary bypass [1, 13, 14].
TAVI is usually performed using transvascular approach
through the femoral artery (transfemoral approach — TFA)
or, the left subclavian artery (transsubclavian approach —
TSA), or via lateral minithoracotomy through the left ventri-
cular (LV) apex (transapical approach — TAA). Occasionally,
the procedure is performed through the ascending aorta via
ministernotomy.
The purpose of this study was to compare periprocedu-
ral and 30-day outcomes of TAVI using transvascular (TFA/
/TSA) or TAA approach in patients with severe AS who were
not candidates for surgical treatment.
METHODS
CoreValve and Edwards Sapien devices
The CoreValve prosthesis (Medtronic Inc.), made from porci-
ne pericardium and mounted on a self-expanding nitinol stent,
is implanted using an 18 F system designed for subclavian,
femoral, and iliac arteries with the lumen diameter of at least
6.5 mm. The device is manufactured in two sizes, 26 and
29 mm, and dedicated for patients with the native aortic an-
nulus diameter ranging from 19 to 27 mm. It has received the
CE mark for transvalvular implantation only (through the com-
mon femoral artery or the left subclavian artery).
Edwards-Sapien and Edwards-Sapien XT prostheses
(Edwards Lifesciences) are made for bovine pericardium and
mounted on a balloon-expanded cobalt-chromium (previo-
usly stainless steel) stent. For transvalvular implantation of the
device, a new 18 F system is currently used, designed for
arteries with the lumen diameter of at least 7 mm (in our
center, 6 out of 8, i.e. 75% of patients were treated using 22 F
and 24 F systems). The device is manufactured in two sizes,
23 and 26 mm, and dedicated for patients with the native
aortic annulus diameter ranging from 17 to 24.5 mm. The
Edwards-Sapien device has received the CE mark for both
transvalvular and transapical implantation.
Patient selection
Patients with symptomatic AS selected for TAVI were not can-
didates for surgical treatment due to high operative risk (logi-
stic Euroscore > 20% coronary artery disease, end-stage re-
nal failure requiring dialysis treatment, chronic pulmonary
disease, pulmonary hypertension defined as pulmonary arte-
ry systolic pressure > 60 mm Hg) or other contraindications
to surgery that are not included in the risk scores (“porcelain”
aorta, previous chest radiotherapy, previous pulmonary lo-
bectomy, severe osteoporosis with chest deformities and/or
leading to delayed sternal wound healing in patients with
a history of compression spinal fractures, cirrhosis with portal
hypertension, previous chest surgery, cognitive dysfunction
due to neurological disease). During evaluation for TAVI, trans-
thoracic (TTE) and transoesophageal (TEE) echocardiography
was performed to assess aortic valve morphology, diameters
of the aortic annulus, aortic root, and ascending aorta (Fig. 1),
aortic valve area, and peak and mean transvalvular gradient.
In addition, computed angiotomography (angio-CT) was per-
formed to assess the anatomy of aortic valve, aortic root, and
the ascending aorta, the distance between coronary ostia and
the aortic valve, aortic anatomy including the presence of
calcifications and thrombi, and the diameter and the course
(tortuosity) of iliac and femoral arteries (Fig. 2A, B). Invasive
angiographic evaluation was also performed to assess angle
between left ventricle and ascending aorta, dimensions of co-
ronary sinuses and aortic root, the diameter and the course
of the ascending aorta, and the diameter and the course of
iliac and femoral arteries.
Figure 1. Transoesophageal echocardiography. Evaluation of
the aortic annulus diameter
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In patients selected for TAVI, the primary approach we
considered was TFA.
Contraindications for TFA included massive calcifications,
tortuosity or small diameter of iliac or common femoral arte-
ries (< 6.5 mm for the CoreValve device, < 7 mm for the
Edwards-Sapien system), abdominal and/or thoracic aortic
aneurysm, “porcelain” ascending aorta, and previous surgery
involving these vessels.
Device type was selected based on measurements perfor-
med during invasive angiography, TTE, TEE and angio-CT (aor-
tic annulus diameter, height of coronary sinuses, width of co-
ronary sinuses, ascending aorta diameter) and the planned ap-
proach during TAVI, with TFA being the approach of choice. If
TFA was contraindicated, patients were considered for TSA. If
both TFA and TSA were not feasible, we selected TAA, possi-
ble only with the use of the Edwards-Sapien system.
Patients
The present analysis includes 30 consecutive patients who
underwent TAVI. All patients were informed of the proce-
dural details and risk and gave written informed consent for
this treatment. All procedures were performed in our de-
partment between January 8, 2009, and May 13, 2010. All
patients were referred for TAVI due to previous disqualifica-
tion from surgery and high operative risk (mean logistic Eu-
roscore 29.18 ± 16.9%). Baseline characteristics of the pa-
tients are shown in Table 1.
Valve implantation procedure
All procedures were performed in a cardiac catheterisa-
tion laboratory by the heart team that included invasive
cardiologists, cardiac surgeons, vascular surgeon, anaesthe-
siologist, echocardiographer, invasive cardiac nurses and
surgical nurses, and radiology technicians. Procedures were
done under angiographic and TTE (CoreValve system) or
TEE (Edwards-Sapien system) guidance, in general or local
anaesthesia and sedation, without the use of cardiopul-
monary bypass. Vascular access was obtained by cannula-
tion of the right or left common femoral artery, with post-
procedural vascular access closure using the ProStar XL
system (n = 13), or by surgical exploration of the femoral
or subclavian artery that was surgically sealed after the pro-
cedure (n = 6).
Transapical device implantation (n = 11) was perfor-
med by left anterolateral minithoracotomy, with postproce-
dural surgical closure of the apex and the chest wall with
left pleural drainage.
Before the procedure, a temporary pacing lead was inser-
ted into the right ventricle through a jugular or femoral vein.
Device implantation was always preceded by balloon valvulo-
Figure 2. Computed angiotomography. Evaluation of the anatomy of the aortic valve, left ventricular outflow tract, aortic root and
ascending aorta, and the distance between coronary ostia and the aortic valve (A). Evaluation of calcifications and thrombi, and the
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plasty of the stenosed aortic valve during rapid (160–200/min)
cardiac pacing. The device was implanted into the aortic an-
nulus under fluoroscopic guidance. Self-expandable CoreVa-
lve device was implanted during basic heart rhythm (Fig. 3),
and balloon-expandable Edwards-Sapien valve was expanded
using a balloon during rapid cardiac pacing (Fig. 4). Details of
the implantation process were presented previously [8, 9, 12,
15–19]. The position and function of the implanted valve was
evaluated angiographically and echocardiographically. If mo-
derate/severe perivalvular regurgitation was found, the device
was expanded using an appriopriately sized balloon during ra-
pid cardiac pacing (in 6/30, or 20% of patients). After the pro-
cedure, patients were transported to an intensive care unit or
a postoperative room.
In-hospital and 30-day follow-up
The effectiveness of TAVI was evaluated immediately after
the procedure by direct (invasive) pressure gradient measure-
ments and also using TTE or TEE. Before discharge, procedu-
ral results were verified clinically and echocardiographically
(TTE). Follow-up visits were scheduled in our department at
30 days, 3, 6 and 12 months, and every 6 months thereafter.
Follow-up evaluation included history, physical evaluation,
Table 1. Baseline patient characteristics
Variable TFA/TSA (n = 19) TAA (n = 11) P
Age [years] 82.05 ± 5.4 83.18 ± 6.35 NS
Women 12/19 (66.6%) 9/11 (81.8%) NS
Logistic Euroscore [%] 22.72 ± 12.07 34.60 ± 15.4 0.03
NYHA class 3.21 ± 0.4 3.27 ± 0.44 NS
Max. aortic gradient [mm Hg] 92.84 ± 20.56 111.27 ± 19.56 0.03
Aortic valve area [cm2] 0.66 ± 0.11 0.7 ± 0.14 NS
Aortic annulus diameter 22.87 ± 1.16 22 ± 1.34 NS
Pulmonary artery pressure 53.6 ± 11.41 58.6 ± 11.38 NS
LVEF < 50% 7/19 (36.84%) 4/11 (36.36%) NS
LVEF [%] 53.7 ± 12.6% 50.9 ± 13% NS
Coronary artery disease: 14/19 (73.68%) 8/11 (72.72%) NS
Previous MI 3/19 (15.79%) 4/11 (36.36%) NS
Previous PTCA 6/19 (31.58%) 5/11 (45.45%) NS
Previous CABG 1/19 (5.26%) 1/11 (9.09%) NS
Peripheral arterial disease 6/19 (31.58%) 8/11 (72.72%) 0.03
Carotid artery disease 2/19 (10.5%) 3/11 (27.27%) NS
COPD 7/19 (36.84%) 5/11 (45.45%) NS
Pulmonary hypertension 11/19 (57.9%) 8/11 (72.72%) NS
GFR 58.32 ± 16.76 49.5 ± 16.63 NS
Osteoporosis 3/19 (15.79%) 1/11 (9.09%) NS
”Porcelain” aorta 0 1/11 (9.09%) NS
Pulmonary hypertension was defined as peak pulmonary artery systolic pressure ≥ 60 mm Hg; NYHA — New York Heart Association; LVEF — left
ventricular ejection fraction; MI — myocardial infarction; PTCA — percutaneous transluminal coronary angioplasty; CABG — coronary artery bypass
grafting; COPD — chronic obstructive pulmonary disease; GFR — glomerular filtration rate
Figure 3. The CoreValve device in the aortic annulus, successful-
ly implanted using the transfemoral approach. Control injection
of the contrast agent to the ascending aorta is seen after the
device was separated from the insertion catheter
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general clinical assessment, data regarding adverse events, TTE
(or TEE in selected patients for better device visualisation),
ECG, and routine biochemical testing.
Database and statistical analysis
Patient demographic data, procedural details, and data from
periprocedural and 30-day follow-up were collected in
a computerised database. Continuous variables are shown
as mean values ± SD, and categorical variables as percenta-
ges. Two-sided Student t test for paired samples was used
to compare selected clinical and echocardiographic data in
both groups. A p value < 0.05 was considered statistically
significant.
RESULTS
Among 38 patients initially selected for TAVI, the procedure was
performed in 30 (79%) patients (TAA n = 11; TFA n = 18; TSA
n = 1). Two (5.2%) patients did not give consent for the pro-
cedure. Two (5.2%) patients died following the initial qualifi-
cation due to complications of severe AS. In two (5.2%) pa-
tients, anatomy was found to be not favourable for TAVI (an-
nulus diameter > 27 mm). Two (5.2%) patients were ultima-
tely treated medically due to comorbidities and relatively short
life expectancy. Mean patient age in those treated with TAVI
was 82.46 ± 5.79 years, and predicted mean surgical morta-
lity using logistic Euroscore was 29.18 ± 16.9% (Table 1).
TAVI procedure
Successful device implantation was performed in 29 (96%) pa-
tients. In one patient in the TFA group, 24 F vascular sheath
could not be passed through the common iliac artery and the
device was not implanted; the only treatment performed was
balloon aortic valvuloplasty that reduced the transvalvular gra-
dient from 70 to 35 mm Hg in echocardiographic evaluation.
One patient needed implantation of second Edwards-Sapien
device during the same procedure due to a leak through one of
the leaflets of valve prosthesis and severe aortic regurgitation (“va-
lve-in-valve” implantation). In another patient, a CoreValve de-
vice was implanted too low, resulting in poorly tolerated periva-
lvular aortic regurgitation. During another session, the device was
repositioned using a loop, resulting in reduction of the regurgi-
tant jet and significant clinical improvement. None of the pa-
tients required cardiopulmonary resuscitation or cardiopulmo-
nary bypass during the procedure. Two patients required small
doses of catecholamines during and shortly after the procedure.
Transapical approach during TAVI was related with si-
gnificantly lower amounts of the contrast agent used and shor-
ter fluoroscopy duration, but the total procedure time was
longer during transpical approach compared to the transva-
scular approach (Table 2).
Immediate results and in-hospital follow-up
Overall in-hospital mortality was 3.3% (TAA 9% vs TFA 0%,
p = 0.19). One patient in the TAA group died several hours
Table 2. The procedure and hospitalisation
Variable TFA/TSA (n = 19) TAA (n = 11) P
Amount of contrast agent [mL] 210 ± 63 159 ± 51 0.03
Fluoroscopy duration [min] 37.7 ± 22 18.7 ± 5.6 0.01
Procedure duration [min] 174 ± 32 221 ± 58 0.046
Successful implantation 18/19 (94.7%) 11/11 (100%) NS
Max. aortic gradient after TAVI [mm Hg] 22.32 ± 10.39 19.7 ± 7.8 NS
Significant aortic regurgitation 0/19 (0%) 0/11 (0%)  
In-hospital mortality 0/19 (0%) 1/11 (9%) NS
Duration of hospitalisation [days] 11.8 ± 8.52 18 ± 10.78 NS
Figure 4. Implantation of the Edwards-Sapien device under
transoesophageal echocardiography guidance using the
transapical approach. This angiogram shows a 22 F sheath
introduced to the left ventricle by myocardial puncture in the
apical area (lower right) and transoesophageal echocardiogra-
phy probe (upper left). Balloon inflation and valve implantation
into the native aortic valve is seen
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after the procedure due to rupture of the native aortic annu-
lus, despite urgent cardiac surgery. This complication most
likely resulted from implantation of a too large Edwards-
-Sapien device. In all patients, substantial reduction of the
transvalvular aortic gradient was seen both in direct measure-
ments immediately after the procedure and in the follow-up
TTE performed before discharge (mean maximal gradient
99.6 ± 22.07 mm Hg before TAVI vs 21.83 ± 9.38 mm Hg
after TAVI). Although preprocedural maximal aortic gradient
was significantly higher in the TAA group (p = 0.027), equal-
ly good results of the procedure were seen in both groups.
Except for one (3.3%) patient requiring reposition of the
CoreValve device using a loop due to significant regurgita-
tion, we did not observed significant trans- or perivalvular re-
gurgitation either immediately after the procedure or in the
follow-up TTE performed before discharge (Table 2).
Except for one patient who required urgent cardiac sur-
gery and died, as noted above, we did not see any other se-
rious adverse events during hospitalisation such as myocar-
dial infarction, cardiogenic shock, stroke/transient ischaemic
attack, or need for cardiopulmonary resuscitation or cardio-
pulmonary bypass. Due to atrioventricular conduction distur-
bances, a cardiac pacemaker was implanted following TAVI
in 9 (30%) patients, including two (18%) in the TAA group
and seven (36.8%) in the TFA/TSA group. Pleural effusion was
seen in two patients after TAA. One patient was treated with
pleuracentesis and evacuation of approx. 1000 mL of fluid,
and the other patient was treated medically. Peripheral em-
bolism was seen in one patient in the TFA group, leading to
worsening of pre-existing foot gangrene. Following vascular
surgeon consultation, partial foot amputation was subsequ-
ently performed. One patient with a history of peptic ulcer
disease in the TFA group experienced massive upper gastro-
intestinal bleeding following TAVI and was transferred to
a department of gastrointestinal surgery for operative treat-
ment. One patient in the TFA group required stent implanta-
tion due to iatrogenic stenosis of the femoral artery that was
previously sealed using the ProStar system. Three patients,
including two in the TFA group and one in the TAA group,
experienced inguinal haematoma in the first few days follo-
wing TAVI. One of these patients required surgical treatment.
Transient disorientation was seen in the first days after the
procedure in two patients in the TAA group, responding to
hydration. In one patient in the TAA group, thrombocyto-
penia resulting in significantly prolonged hospital stay was
seen, probably due to heparin administration during TAVI.
Overall, the mean duration of hospitalisation after the pro-
cedure was 14.5 ± 9.47 days (18 ± 10.78 days in the TAA
group vs 11.8 ± 8.52 days in the TFA/TSA group). In-hospital
complications are summarised in Table 3.
30-day follow-up
During 30-day follow-up, one (3.3%) patient in the TAA group
died suddenly at home, three weeks after TAVI. At 30 days,
three (10%) patients were still hospitalised, including the pa-
tient with thrombocytopenia in the TAA group and two pa-
tients in the TFA/TSA group — one who underwent partial
foot amputation and one who underwent surgical treatment
of the upper gastrointestinal bleeding, respectively. The re-
maining patients did not require any additional hospitalisa-
tions. No patient experienced other serious cardiac adverse
events or worsening of the renal failure requiring dialysis the-
rapy. 28 patients showed up for the 30-day follow-up visit,
with evaluation including history, physical examination, ECG,
TTE and basic laboratory tests. Overall, mean exercise tole-
rance as measured using the New York Heart Association
(NYHA) classification improved from 3.23 ± 0.41 before the
procedure to 1.72 ± 0.52 at 30 days after the procedure
(p = 0.03). Data on NYHA class in both groups at baseline and
at 30 days are shown in Tables 1 and 4. Overall, mean maxi-
mal aortic gradient in TTE at 30 days after TAVI was 23.25 ±
± 9.22 mm Hg, and 30-day mortality was 6.6% (18% in the
Table 3. Complications of TAVI
Variable TFA/TSA (n = 19) TAA (n = 11) P
Urgent cardiac surgery 0 1 (9%) NS
Periprocedural death 0 1 (9%) NS
Myocardial infarction/cardiogenic shock 0 0  
Stroke/transient ischaemic attack 0 0  
Pacemaker implantation 7 (36.9%) 2 (18%) NS
Pleural effusion 0 2 (18%) NS
Peripheral embolism 1 (5.26%) 0 NS
Gastrointestinal bleeding 1 (5.26%) 0 NS
Iatrogenic femoral artery stenosis 1 (5.26%) 0 NS
Inguinal haematoma 3 (15.79%) 2 (18%) NS
Thrombocytopenia 0 1 (9%) NS
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TAA group vs 0% in the TFA/TSA group; p = 0.05). Selected
clinical and echocardiographic data at 30-day follow-up are
shown in Table 4.
DISCUSSION
The first TAVI procedure was performed through the femo-
ral vein and interatrial septum by Cribier in 2002. Two years
later, in July 2004, cardiologists Laborde, Lal and Grube per-
formed the first transarterial aortic valve implantation, and
in November 2005, invasive cardiologist Webb and cardiac
surgeon Lichtenstein implanted the aortic valve into a be-
ating heart using LV transapical approach. The first trans-
catheter TAVI implantation was performed by invasive car-
diologists Serruys, DeJaegere and Laborde in October 2006
[4, 6, 17, 20].
The first TAVI procedure in Poland was performed in
November 2008 in Cracow, and Zabrze, Katowice and War-
saw-Anin soon followed. By September 2010, approx. 160 im-
plantations of Edwards Sapien and CoreValve devices were
performed in 10 centres in Poland. First results of transcathe-
ter treatment of patients with AS in Poland were presented in
the POL-TAVI-First registry [21] and by Kapelak et al. [22].
Since the very first TAVI, it has been debated which of
these approaches is the most effective and the safest. Mini-
thoracotomy with opening of the pleura and the pericar-
dium and LV apical puncture, required for transapical im-
plantation, is more invasive and probably should be perfor-
med in the hybrid operation theatre. However, they allow
avoidance of quite aggressive manipulation within periphe-
ral arteries and aortic arch, and the duration of the implan-
tation procedure is shorter. According to the 2008 Europe-
an Association of Cardiac and Thoracic Surgeons (EACTS)
guidelines, TAVI should be offered to patients with AS who
were disqualified from surgery due to high operative risk or
other contraindications to surgery, and the choice of im-
plantation approach is left to the discretion of the operator
[1, 23].
In our study, transcatheter treatment was offered to pa-
tients with a very high risk of surgical AVR, as determined by
thorough evaluation of the clinical condition of the patient,
comorbidities, and the predicted operative risk estimated
using logistic Euroscore. In two female patients aged 83 and
77 years, we decided to perform TAVI following surgical di-
squalification despite relatively low values of logistic Eurosco-
re (15.9% and 6.59%) due to advanced osteoporosis with com-
pression fractures of thoracic and lumbar vertebrae.
In patients scheduled for TAVI, transfemoral approach
was initially considered. If TFA was contraindicated (in 40%
of patients in our group), we considered TSA and this appro-
ach was selected in one (3.3%) patient. The TAA was selec-
ted in 11 (36.6%) of our patients with contraindications to
both TFA and TSA.
The algorithm of TAVI approach selection is primarily
based on the presence of comorbidities. Advanced periphe-
ral arterial disease is a contraindication to TFA and thus it was
more prevalent in the TAA group (73% vs 31%; p = 0.02). In
addition, a diffuse nature of atherosclerosis results in more
prevalent coronary and carotid artery disease in these patients,
with all clinical consequences such as history of myocardial
infarction, percutaneous transluminal coronary angioplasty or
coronary artery bypass grafting that was twice as common in
the TAA group than in the TFA/TSA group, although the dif-
ference was not statistically significant due to low numbers of
patients (Table 1). Other contraindications to TFA include
small diameter (< 6.5–7 mm), tortuous course and extensive
calcification in common femoral arteries, iliac arteries and/or
aorta, “porcelain” aorta, and a horizontal course of the ascen-
ding aorta.
Despite these comorbidities and baseline differences
between the two groups, as reflected by mean logistic Euro-
score (34.6% in the TAA group vs 22.7% in the TFA/TSA
group; p = 0.03), the choice of implantation approach had
no significant effect on the effectiveness of treatment as eva-
luated both immediately after the procedure (Table 2) and
at 30 days (Table 4). In published registries and observatio-
nal studies, 30-day mortality following TAVI using TFA/TSA
ranged from 0% to 25% [8, 9, 19, 24–27]. In our group of
19 patients who underwent TAVI using TFA/TSA, we did not
Table 4. Results at 30-day follow-up
Variable TFA/TSA (n = 19) TAA (n = 9) P
Age [years] 82.05 ± 5.4 83.18 ± 6.35 NS
Women 12/19 (66.6%) 9/11 (81.8%) NS
NYHA class 1.78 ± 0.55 1.6 ± 0.48 NS
Max. aortic gradient [mm Hg] 24.7 ± 10.4 20.7 ± 6.1 NS
Significant aortic regurgitation 0/18 (0%) 0/10 (0%)  
Left ventricular ejection fraction < 50% 7/19 (36.84%) 4/11 (36.36%) NS
Left ventricular ejection fraction [%] 59.8 ± 8.8% 59.4 ± 9.8% NS
Death 0 (0%) 2 (18%) 0.05
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see any deaths both in the periprocedural period and at
30 days. In other reports regarding TAVI using TAA (performed
in groups of 26–59 patients), 30-day mortality was 8–23%
[16, 28–31]. In our study, 2/11 (18%) patients died among
these treated with TAVI using TAA.
In addition to the previously noted problems and co-
morbidities, complications specific for the implantation ap-
proach have been reported in the literature regarding TAVI.
Complications reported in patients treated using transvascu-
lar approach include rupture of a peripheral vessel, acute ar-
terial occlusion or stenosis, and severe bleeding requiring va-
scular surgical intervention. These complications occurred in
9–20% patients treated with TFA/TSA [9, 19, 24–27].
In contrast, patients undergoing TAVI with TAA are most
likely to experience chest wall bleeding, and occasionally ble-
eding from the site of the LV apex puncture. Surgical inte-
rvention for bleeding was necessary in 8–14% of patients tre-
ated using TAA [16, 30, 31]. Other rare but severe complica-
tion of TAA is the development of a LV pseudoaneurysm [32].
In our patients, we saw typical complications related to
the route of the device implantation (Table 3). Evaluation with
TTE at 30 days did not show other problems reported in the
literature [30–32] such as LV wall motion abnormalities, thin-
ning or weakening in the apical area. Published data show
that valve implantation using TAA is associated with 9–12%
risk of conversion to cardiac surgical procedure, while the
use of cardiopulmonary bypass is required in 10–30% of pa-
tients [1]. In our group treated using TAA, only one (9%) pa-
tient required cardiac surgical intervention due to rupture of
the aortic annulus.
In summary, acute complications related to the implan-
tation approach for TAVI may occur with both TAA and TFA,
may be potentially life-threatening and require urgent and
careful invasive or surgical treatment [1]. Of note, according
to the latest reports, mainly from the Source Registry, vascu-
lar complications of TFA/TSA do not lead to increased in-
hospital mortality in contrast to TAA complications [33].
Apart from approach-specific complications, outcomes
may also be affected by differences in the implantation pro-
cedure itself. The TAA is easier and more controllable for the
operator, and it does not require angiography of the aortic
bifurcation, iliac arteries, and femoral arteries. Thus, the amo-
unt of contrast used and fluoroscopy time are reduced, al-
though the procedure is longer to complete and requires ge-
neral anaesthesia.
Pacemaker implantation related to atrioventricular con-
duction disturbances has been more frequently reported follo-
wing the CoreValve device implantation (25%) and is less fre-
quent among patients treated with balloon-expandable valves
(4–8%) [1]. This problem is related to differences in valve de-
sign, its anchoring, and radial forces generated by a large niti-
nol frame of the CoreValve device that act on the subvalvular
region of the LV, and particularly the interventricular septum.
In our study group, patients in the TFA/TSA group required
pacemaker implantation more often than patients in the TAA
group (2/11 patients, or 18%, in the TAA group vs 7/19 pa-
tients, or 37%, in the TFA/TSA group; p = 0.29). Overall, pa-
cemaker insertion was necessary in 3/18 (16%) of patients tre-
ated with balloon-expandable Edwards-Sapien device, com-
pared to 6/11 (54%) of patients treated with self-expandable
CoreValve device with a nitinol frame (p = 0.025).
So far, it has not been proven that TAA leads to reduction
of neurological complications. Review of the available litera-
ture indicates, however, that the risk of a neurological event
in patients treated using TAA is 0–5% [16, 31, 34], compared
to 0–20% among patients treated using TFA [9, 19, 24–26].
These differences may be related to the need of manipulating
a relatively stiff transfemoral valve implantation system within
the aortic arch. In our study, we noted no serious neurological
complications in any of the patients in both groups.
As with all new treatment modalities, some complica-
tions may be related to the learning curve [19]. Our data from
the immediate and 30-day follow-up are consistent with such
a possibility. In-hospital mortality was 6.6% (1/15) among the
first 15 patients and (0/15) among the remaining 15 patients.
CONCLUSION
In our opinion, good results of TAVI depend on proper pa-
tient selection including careful consideration of contraindi-
cations to TAA/TFA/TSA and AVR, and the experience of the
heart team. Final decisions should be taken by a heart team
including clinical cardiologists, invasive cardiologists and car-
diac surgeons, taking into account the clinical condition of
the patient and full spectrum of diagnostic data including ima-
ging studies. Our experience with the first 30 patients indica-
tes that transvascular TAVI approach (TFA/TSA) is associated
with lower risk of complications, including mortality, during
30-day follow-up. It should be stressed, however, that the
availability of several alternative implantation approaches re-
sulting in a larger number of patients with AS referred for TAVI
who may ultimately benefit from this treatment modality.
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Przezcewnikowa implantacja zastawki aortalnej
z dostępu naczyniowego i przezkoniuszkowego:
obserwacje 30−dniowe 30 pierwszych pacjentów
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S t r e s z c z e n i e
Wstęp i cel: Celem niniejszej pracy jest porównanie wyników przezcewnikowej implantacji zastawki aortalnej (TAVI),
z dostępu przeznaczyniowego [od tętnicy udowej (TFA) lub podobojczykowej (TSA)] i przezkoniuszkowego (TAA) u pacjen-
tów z ciężkim zwężeniem zastawki aortalnej zdyskwalifikowanych z leczenia chirurgicznego w okresie bezpośrednio po
zabiegu i w obserwacji 30-dniowej.
Metody: Analizą objęto 30 kolejnych pacjentów poddanych zabiegowi TAVI z dostępu TFA (18 osób), TSA (1 chory) lub TAA
(11 pacjentów). Wszystkie zabiegi wykonano w Samodzielnej Pracowni Hemodynamicznej IK w Warszawie między 8.01.2009
a 13.05.2010 r. Dostępem pierwszego wyboru był TFA, natomiast drugiego wyboru — TAA, przy przeciwwskazaniach do TFA.
Przeciwwskazaniem do TFA były masywne zwapnienia, kręty przebieg lub mała średnica tętnic biodrowych lub udowych
wspólnych (< 6,5 mm dla zastawek CoreValve i < 7 mm dla systemu Edwards-Sapien), tętniaki aorty brzusznej i/lub piersiowej,
„porcelanowa” aorta wstępująca bądź wywiad wcześniejszych zabiegów chirurgicznych tych naczyń. We wszystkich przypad-
kach implantowano protezy Edwards-Sapien lub CoreValve. Zabiegi przeprowadzono bez krążenia pozaustrojowego.
Wyniki: Średni wiek pacjentów wynosił 82,46 ± 5,79 roku, klasa NYHA przed zabiegiem 3,23 ± 0,41, a przewidywane średnie
ryzyko zgonu operacyjnego obliczone z zastosowaniem skali logistic Euroscore 29,18 ± 16,9% (TAA 34,6 ± 15,4% v. TFA/TSA
22,72 ± 12,07%; p = 0,031). Skuteczną implantację protezy przeprowadzono u 96% chorych. Całkowita śmiertelność szpital-
na wyniosła 3,3% (TAA 9% v. TFA 0%; p = 0,19). W obserwacji 30-dniowej śmiertelność w całej grupie wyniosła 6,6% (TAA 18%
i TFA/TSA 0%; p = 0,05). W trakcie hospitalizacji nie odnotowano poważnych zdarzeń, takich jak zawał serca, wstrząs, przemi-
jający atak niedokrwienny/udar mózgu, konieczność zastosowania resuscytacji krążeniowo-oddechowej czy krążenia poza-
ustrojowego. Jeden pacjent zmarł nagle 3 tygodnie po TAVI. W obserwacji 30-dniowej nie zanotowano innych poważnych
zdarzeń kardiologicznych. Po TAVI stwierdzono znamienną redukcję gradientu w obu grupach (z 99,6 ± 22,07 mm Hg do
21,83 ± 9,38 mm Hg po zabiegu i do 23,25 ± 9,22 mm Hg w obserwacji 30-dniowej), nie zaobserwowano ciężkiej niedomy-
kalności aortalnej. Klasa wg NYHA w obserwacji 30-dniowej zmniejszyła się z 3,23 ± 0,41 do 1,72 ± 0,52 (p = 0,03).
Wnioski: Na podstawie doświadczeń autorów niniejszej pracy można sądzić, że zabiegi TAVI TFA/TSA wiążą się z mniej-
szym ryzykiem powikłań, w tym zgonu, w obserwacji 30-dniowej. Jednak możliwość zaproponowania chorym z ciężką AS,
niekwalifikującym się do leczenia chirurgicznego, kilku alternatywnych sposobów implantacji zastawki, zwiększa grupę pa-
cjentów mogących skorzystać z tej metody terapii.
Słowa kluczowe: przezcewnikowa implantacja zastawki aortalnej, stenoza aortalna
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